BDSI BioDelivery Sciences International Inc.

4.97
+0.17  (+4%)
Previous Close 4.8
Open 4.84
Price To Book 6.72
Market Cap 444,929,469
Shares 89,523,032
Volume 1,637,278
Short Ratio
Av. Daily Volume 578,150
Stock charts supplied by TradingView

NewsSee all news

  1. Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

    Calidi Biotherapeutics, Inc. ("Calidi"), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George

  2. Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

    Deep Clinical-Stage Pipeline Combined With World-Class Leadership TeamOrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company

  3. BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®

    Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred or Preferred Exclusive RALEIGH, N.C.,

  4. BioDelivery Sciences Announces Participation in Upcoming Investor Conferences

    RALEIGH, N.C., Sept. 17, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  5. BioDelivery Sciences Announces Upcoming Investor Conference Presentations

    RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

    Calidi Biotherapeutics, Inc. ("Calidi"), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George

  2. Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

    Deep Clinical-Stage Pipeline Combined With World-Class Leadership TeamOrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company

  3. BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®

    Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred or Preferred Exclusive RALEIGH, N.C.,

  4. BioDelivery Sciences Announces Participation in Upcoming Investor Conferences

    RALEIGH, N.C., Sept. 17, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  5. BioDelivery Sciences Announces Upcoming Investor Conference Presentations

    RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  6. BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management

    RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today